Teaching and motivating patients to control their risk factors retards progression of cardiovascular as well as microvascular sequelae of Type 2 diabetes mellitus - A randomized prospective 8 years follow-up study

Diabetic Medicine

Volumn 22, Issue 4, 2005, Pages 410-414

  Rachmani, R ^a   Slavachevski, I ^a   Berla, M ^a   Frommer Shapira, R ^a   Ravid, M ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Diabetes mellitus; Diabetic complications; Intensive management; Patient education

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TEACHING;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; HUMANS; MIDDLE AGED; MOTIVATION; MYOCARDIAL INFARCTION; PATIENT EDUCATION;

EID: 17144417220     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01428.x     Document Type: Article

References (18)

1. Gary TL, Gentringer JM, Guallar E, Peyrot M, Brandcati FL. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ 2003; 29: 488-501.
2. Murata GH, Shah JH, Adam KD, Wendel CS, Bokhari SU, Sulvan PA et al. Factors affecting diabetes knowledge in type 2 diabetic veterans. Diabetologia 2003; 46: 1170-1178.
3. Alazvi MH, Neal RD. The association between satisfaction with services provided in primary care and outcomes in type 2 diabetes mellitus. Diabet Med 2003; 20: 486-490.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998; 352: 837-853.
5. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. Br Med J 1998; 317: 703-713.
6. Sawicki PT, Mullhanser I, Didjurgeit M, Reimann M, Bender R, Berger M. Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro or macroproteinuria. Diabet Med 1995; 12: 893-898.
7. Hansson L, Zanchetti A, Julius S, on behalf of the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) Randomized Trial. Lancet 1998; 351: 1755-1762.
8. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 Randomized Study. Lancet 1999; 353: 617-622.
9. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med 2003; 348: 383-393.
10. Rachmani R, Levi Z, Slavachevski I, Avin M, Ravid M. Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with type 2 diabetes mellitus - a randomized prospective study. Diabet Med 2002; 19: 385-392.
11. Levy AS, Bosch JP, Breyer Lewis J, Green T, Togers N, Toth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 4461-4470.
12. Pyorala K, Pedersen TR, Kjekshus J, Fargeman O, Olsson AC, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
13. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
15. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
16. Kanters SDJM, Algra A, de Bruint TWA, Erkelens DM, Banga JD. Intensive lipid lowering strategy in patients with diabetes mellitus. Diabet Med 1999; 16: 500-508.
17. Holt W, Johnson A, de Belder M. Patient empowerment in secondary prevention of coronary heart disease. Lancet 2000; 356: 314.
18. White WB, Asmar R, Imai Y. Task force VI: self monitoring of the blood pressure. Blood Press Monit 1999; 4: 343-351.